Conatus Pharmaceuticals is a biotechnology company focused on the development and commercialization of novel medicines to treat chronic diseases with significant unmet need. The Company's lead in-licensed compound, emricasan, is being developed in collaboration with Novartis for the treatment of patients with NASH-driven chronic liver diseases. In addition, Conatus' lead internally developed compound, CTS-2090, is targeting the treatment of patients with chronic diseases involving inflammasome pathways. Source
No articles found.
Syros is redefining the power of small molecules to control the expression of gene...
Syros is redefining the power of small molecule...
Audentes Therapeutics is a leading AAV-based genetic medicines company focused on ...
Audentes Therapeutics is a leading AAV-based ge...
At ACADIA (NASDAQ: ACAD), we share a passion for improving the lives of patients w...
At ACADIA (NASDAQ: ACAD), we share a passion fo...
Dermira is a biopharmaceutical company dedicated to bringing biotech ingenuity to ...
Dermira is a biopharmaceutical company dedicate...
Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focu...
Paratek Pharmaceuticals, Inc. is a commercial-s...
Axovant is accelerating the development of innovative gene therapy products that a...
Axovant is accelerating the development of inno...
We are a clinical stage biopharmaceutical company focused on harnessing powerful b...
We are a clinical stage biopharmaceutical compa...
Join the National Investor Network and get the latest information with your interests in mind.